Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 1, 2012CSL Behring is the recipient of a 2012 EURORDIS Award for its pioneering work in developing and manufacturing therapies used to treat rare and serious medical conditions. The global biotherapeutics company, which specializes in plasma-derived and recombinant therapies used to treat congenital bleeding disorders, immune deficiencies, hereditary angioedema and inherited respiratory disease, is a subsidiary of CSL Limited (ASX:CSL).
01 Mar 2012 CSL Behring is the recipient of a 2012 EURORDIS Award for its pioneering work in developing and manufacturing therapies used to treat rare and serious medical conditions. The global...
-
Feb 24, 2012The CSL Behring rFVIII, called 'rVIII-SingleChain', is a novel molecule being studied for the treatment of hemophilia A. It is being developed by CSL Behring, in collaboration with its parent company, CSL Limited (ASX:CSL).
24 Feb 2012 CSL Behring has announced that the first patient has been screened in its recombinant coagulation single-chain factor VIII (rFVIII) trial, part of the AFFINITY clinical trial program....
-
Feb 21, 2012Thought leaders from the medical community in Europe and the U.S. examined the pros and cons of using albumin in treating liver disease and sepsis, and in cardiac surgery, during CSL Behring’s Key Issues Dialogue — "Albumin in Clinical Fluid Management."
21 Feb 2012 Thought leaders from the medical community in Europe and the U.S. examined the pros and cons of using albumin in treating liver disease and sepsis, and in cardiac surgery, during CSL...
-
Feb 16, 2012CSL Behring announced today that the company has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for its novel recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP). The Orphan Drug Designation is granted for the treatment and prophylaxis of bleeding episodes in patients with congenital hemophilia and inhibitors to coagulation factor VIII or IX.
16 Feb 2012 CSL Behring announced today that the company has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for its novel recombinant fusion protein linking...
-
Feb 15, 2012
CSL Behring announced today the four recipients of the 2012 Interlaken Leadership Awards. Now in its second year, the Interlaken Leadership Awards program recognizes scientists whose proposals are...